India has been struggling endlessly with the second wave of the Wuhan virus; has hit the nation like Tsunami infecting around 3.5 lakhs people everyday. This number has reduced and the situation seems to be getting slightly better with the recovery rate also rising to 83.04%. In January this year, India began its vaccination program to curb the virus in the hope that the number of casualties will be lessened. India till now has managed to vaccinate 10.2% of its population with the first dose and 2.9% with both the doses.
Companies like Bharat Biotech have successfully managed to develop their indigenous vaccine called Covaxin which is an achievement in itself. The other company is the Serum Institute of India, which has manufactured Covishield which is the Oxford Astra-Zeneca vaccine. India has been administering its people with mainly Covaxin and Covishield. India’s largest vaccination drive began with vaccinating the frontline workers who have been fighting day and night to serve the people without bothering about their health. In Phase II of the vaccination program, the government decided to vaccinate people 45 years of age and above with co-morbidities. And the third phase began on 1st May, with the government declaring that people of the age 18 years and above can get vaccinated.
Both Bharat Biotech and Serum Institute of India have been manufacturing vaccines with full fledge. Meanwhile, the Central government also declared that over 2 billion doses will be made available between August and December which will be enough to vaccinate almost the entire population of India. Another vaccine that has been approved to be administered in India is Russia’s Sputnik V.
UPDATE on Vaccines
1. Over 216 crore doses of vaccines will be manufactured in India between August-December – for India and for Indians.
2. Any vaccine that is approved by FDA, WHO can come to India & import license will be granted within 1-2 days; No import license pending. pic.twitter.com/fY5g4nEwer
— Prakash Javadekar (@PrakashJavdekar) May 13, 2021
In the midst of all this, the DGCI on the 13th May 2021 released a press statement saying that it has accepted the recommendation Subject Expert Committee (SEC) and given a nod to Bharat Biotech to conduct Phase II/III clinical trials of the Covid-19 vaccine called Covaxin in the age group of 2-18 years of age. The trial will be conducted on 525 healthy volunteers. It has been mentioned in the press release that the vaccine will be given by intramuscular route, in two doses at day 0 and day 28.
The press release also mentioned that the proposal was deliberated in Subject Expert Committee (SEC) (COVID-19) on May 11. The Committee after detailed deliberation recommended for grant of permission to conduct the proposed Phase II/III clinical trial to certain conditions.
Along with Bharat Biotech’s Covaxin getting a green signal to conduct its trial on kids, US drug regulatory USFDA also gave its nod to Pfizer-BioNTech’s Covid-19 vaccine to conduct the vaccine trial on children of the age group 12-15.
The first 10,000 batches of 2DG medicine for curing Covid-19 patients would be launched early next week: DRDO Officials.
DRDO officials said that the first batch of 10,000 doses of 2DG medicine for curing COVID-19 patients would be launched early next week and will be given to patients.
They even said that the drug manufacturers are working on ramping up the production of the medicine for future use. The drug has been developed by a team of DRDO scientists including Dr. Anant Narayan Bhatt.
The first batch of 10,000 doses of 2DG medicine for curing COVID-19 patients would be launched early next week and will be given to patients: DRDO officials pic.twitter.com/DmgDzxFgpd
— ANI (@ANI) May 14, 2021
On 8th May, the Defence Research and Development Organisation (DRDO) which is the R&D wing of the Ministry of Defence, Government of India announced on Twitter that an anti-Covid-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO in collaboration with Dr Reddy’s Laboratories, Hyderabad. The drug will help in the faster recovery of Covid-19 patients.
An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by INMAS, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad. The drug will help in faster recovery of Covid-19 patients. https://t.co/HBKdAnZCCP pic.twitter.com/8D6TDdcoI7
— DRDO (@DRDO_India) May 8, 2021
The Drugs Controller General of India (DGCI) approved the emergency use of drug 2-DG as an adjunct therapy in moderate-to-severe Covid-19 patients. Clinical trials have shown that this molecule has helped in the faster recovery of hospitalized patients and reduced supplemental oxygen dependency.
Hopefully, with the new drug developed by DRDO and the vaccination program ramping up in India, the nation is looking towards getting healed.
DISCLAIMER: This article reflects author’s view point. Goa Chronicle may or may not subscribe to views of the author